Beovu (Brolucizumab) for AMD

Overview
Beovu is approved by the U.S. Food and Drug Administration (FDA) for the treatment of neovascular (wet) age-related macular degeneration (AMD). This medication is typically prescribed to treat vision loss caused by abnormal blood vessels under the retina, which can leak and cause damage. Beovu is also known by its drug name, brolucizumab.

Beovu is a type of medicine called a biologic drug — it is made from living cells. It works by blocking a protein called vascular endothelial growth factor (VEGF), which encourages these abnormal blood vessels to grow. By blocking VEGF, Beovu helps to reduce leaking and swelling in the eye. This helps to stabilize or even improve vision in people with wet AMD. 

How do I take it?
Prescribing information states that Beovu is given as an injection directly into the eye. The typical dosing schedule for Beovu starts with one injection every month for the first three doses, followed by one injection every eight to 12 weeks afterward. The doses can vary for each person based on their needs and response to treatment. Beovu must be given by a qualified doctor.

Side effects
Common side effects of Beovu include eye pain, bleeding under the clear outer layer of the eye, vitreous floaters (tiny spots or threads that drift around in your vision), and blurred vision. Other possible side effects are high pressure inside the eye, eye irritation, and cataracts.

Rare but serious side effects may include allergic reactions, endophthalmitis (eye infection), detached retina, inflammation or blockage of blood vessels in the retina, increased eye pressure, and nonfatal stroke or nonfatal heart attack. Report any new or worsening eye symptoms to your health care provider immediately.

For more information about this treatment, visit:

Beovu — Brolucizumab Injection, Solution — DailyMed

Beovu Prescribing Information — U.S. Food and Drug Administration